[go: up one dir, main page]

MX9301753A - Generacion in vitro de celulas dentriticas humanas y utilizacion de las mismas. - Google Patents

Generacion in vitro de celulas dentriticas humanas y utilizacion de las mismas.

Info

Publication number
MX9301753A
MX9301753A MX9301753A MX9301753A MX9301753A MX 9301753 A MX9301753 A MX 9301753A MX 9301753 A MX9301753 A MX 9301753A MX 9301753 A MX9301753 A MX 9301753A MX 9301753 A MX9301753 A MX 9301753A
Authority
MX
Mexico
Prior art keywords
same
vitro generation
dentritic cells
human
cells
Prior art date
Application number
MX9301753A
Other languages
English (en)
Inventor
Jacques Banchereau
Christophe Caux
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX9301753A publication Critical patent/MX9301753A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

Se proporciona un método para generar céluls dentríticas humanas in vitro, tratando células CD34+ con un factor alfa de necrosis tumoral e interleucina-3 o con GM-CSF.
MX9301753A 1992-03-30 1993-03-29 Generacion in vitro de celulas dentriticas humanas y utilizacion de las mismas. MX9301753A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92400879A EP0563485A1 (en) 1992-03-30 1992-03-30 In vitro generation of human dendritic cells and uses thereof

Publications (1)

Publication Number Publication Date
MX9301753A true MX9301753A (es) 1993-09-01

Family

ID=8211642

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9301753A MX9301753A (es) 1992-03-30 1993-03-29 Generacion in vitro de celulas dentriticas humanas y utilizacion de las mismas.

Country Status (14)

Country Link
EP (2) EP0563485A1 (es)
JP (1) JP3492361B2 (es)
KR (1) KR100223395B1 (es)
AT (1) ATE192189T1 (es)
AU (2) AU682466B2 (es)
CA (1) CA2133316C (es)
DE (1) DE69328481T2 (es)
DK (1) DK0633930T3 (es)
ES (1) ES2145047T3 (es)
GR (1) GR3033761T3 (es)
MX (1) MX9301753A (es)
NZ (1) NZ251585A (es)
PT (1) PT633930E (es)
WO (1) WO1993020186A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333433T2 (de) * 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
DE4337396A1 (de) * 1993-10-26 1995-04-27 Beiersdorf Ag Humane Zellinien mit Langerhans-Zell-Charakteristik
DE4412794A1 (de) * 1994-04-14 1995-12-14 Univ Ludwigs Albert Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US5648248A (en) * 1994-12-30 1997-07-15 Boehringer Ingelheim International Gmbh Methods for producing differentiated cells from immature hematopoietic cells
US6340981B1 (en) 1997-06-30 2002-01-22 Sun Microsystems, Inc. Method and apparatus for stroke substitution
US6010905A (en) * 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US5643786A (en) * 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
US5871728A (en) 1995-03-31 1999-02-16 University Of Pittsburgh Method of regulating dendritic cell maturation
US6121044A (en) * 1995-07-12 2000-09-19 Dendreon Corporation Potent antigen presenting cell composition
US7150992B1 (en) 1995-10-04 2006-12-19 Innunex Corporation Methods of preparing dendritic cells with flt3-ligand and antigen
US7361330B2 (en) 1995-10-04 2008-04-22 Immunex Corporation Methods of using flt3-ligand in the treatment of fibrosarcoma
US6734014B1 (en) 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
CA2245170A1 (en) * 1996-02-08 1997-08-14 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating t cells
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US5811297A (en) * 1996-03-07 1998-09-22 Amba Biosciences, Llc Immortalized hematopoietic cell lines, cell system thereof with stromal cells, in vitro, ex vivo and in vivo uses, & in vitro generation of dendritic cells and macrophages
US6008004A (en) * 1996-10-04 1999-12-28 Becton Dickinson & Company Identification of a CD34+ bone marrow precursor for dendritic cells in blood and lymphoid tissues
JP2001508648A (ja) 1996-11-06 2001-07-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 腫瘍壊死因子レセプター放出酵素、酵素を含む組成物、およびその使用方法
AU9374198A (en) * 1997-09-08 1999-03-29 Idec Pharmaceuticals Corporation Methods for producing human antibodies in scid mice using dendritic cells
EP0922758B1 (en) 1997-10-27 2009-04-15 Rockefeller University Methods and compositions for obtaining mature dendritic cells
US6602709B1 (en) 1998-02-20 2003-08-05 The Rockefeller University Methods for use of apoptotic cells to deliver antigen to dendritic cells for induction or tolerization of T cells
EP1016413A1 (en) * 1998-12-30 2000-07-05 Applied Research Systems ARS Holding N.V. Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
JP2001061469A (ja) * 1999-08-24 2001-03-13 Japan Science & Technology Corp 免疫応答誘導樹状細胞の調製方法
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
AU2002331704A1 (en) 2001-08-22 2003-03-10 The Government Of The United States Of America, Represented By The Secretary, Department Of Health A Peptides of melanoma antigen and their use in diagnostic, prophylactic and therapeutic methods
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
KR100522526B1 (ko) * 2002-11-28 2005-10-19 주식회사 바이넥스 면역 치료용 수지상 세포의 제조방법
WO2004104185A1 (en) 2003-05-08 2004-12-02 Xcyte Therapies, Inc. Generation and isolation of antigen-specific t cells
CA2577125C (en) 2004-10-07 2016-01-12 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
WO2007055902A1 (en) 2005-11-03 2007-05-18 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Immunogenic peptides and methods of use for treating and preventing cancer
CA2705486C (en) 2007-11-19 2019-04-02 Celera Corporation Lung cancer markers and uses thereof
ES2514590T3 (es) 2008-09-02 2014-10-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Nuevo péptido antígeno del melanoma y usos del mismo
EP2714730A1 (en) 2011-06-01 2014-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel antigen peptide and uses thereof
ES2753392T3 (es) 2012-05-22 2020-04-08 Inst Nat Sante Rech Med Nuevo péptido antigénico de melanoma y usos del mismo
AU2012380681A1 (en) 2012-05-22 2014-10-30 Centre National De La Recherche Scientifique (Cnrs) Novel melanoma antigen peptide and uses thereof
EP3126374B1 (en) 2014-04-01 2018-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) An isolated donor mhc-derived peptide and uses thereof
US10105425B2 (en) 2014-04-01 2018-10-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Isolated donor MHC-derived peptide and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002531A1 (en) * 1989-08-17 1991-03-07 Peter Maccallum Cancer Institute Method for the modulation of haemopoiesis in a mammal
US5128259A (en) * 1989-10-27 1992-07-07 Hahnemann University Factor-dependent hematopoietic cell line exhibiting epo-induced erythrocyte maturation
US5622853A (en) * 1990-05-01 1997-04-22 Becton Dickinson And Company T lymphocyte precursor

Also Published As

Publication number Publication date
DK0633930T3 (da) 2000-09-18
ATE192189T1 (de) 2000-05-15
EP0563485A1 (en) 1993-10-06
ES2145047T3 (es) 2000-07-01
DE69328481T2 (de) 2000-09-07
JPH07505527A (ja) 1995-06-22
CA2133316A1 (en) 1993-10-14
AU3155897A (en) 1997-11-20
WO1993020186A1 (en) 1993-10-14
GR3033761T3 (en) 2000-10-31
KR950700989A (ko) 1995-02-20
NZ251585A (en) 1997-07-27
CA2133316C (en) 2005-05-24
JP3492361B2 (ja) 2004-02-03
PT633930E (pt) 2000-09-29
KR100223395B1 (ko) 1999-10-15
DE69328481D1 (de) 2000-05-31
AU682466B2 (en) 1997-10-09
EP0633930A1 (en) 1995-01-18
AU3928993A (en) 1993-11-08
EP0633930B1 (en) 2000-04-26

Similar Documents

Publication Publication Date Title
MX9301753A (es) Generacion in vitro de celulas dentriticas humanas y utilizacion de las mismas.
NO20001583D0 (no) Stimulering av hematopoetiske celler in vitro
DE69738731D1 (de) SIALYL-LEWISa UND SIALYL-LEWISx EPITOPE ANALOGE
PT1040112E (pt) Imidazonaftiridinas e sua utilizacao na inducao da biosintese das citoquinas
MX9405383A (es) Imidazo(4,5-c) piridin-4-aminas.
DE3780316D1 (de) Verwendung von interleukin-1 zur induzierung der bildung von multipotenten haemopoietischen zellpopulationen.
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
KR970702733A (ko) 활성물질의 방출 조절용 콜라겐 제제(collagen preparation the controlled release of active substances)
DK0552243T3 (da) Anvendelse af interleukin-4 til behandling af faste tumorer
UA66793C2 (uk) Лептин як стримувач швидкого збільшення пухлини клітини
IL150984A0 (en) Modified cytokines for use in cancer therapy
ATE432978T1 (de) T-zellaktivierung
ES2095846T3 (es) Composicion estable y liofilizada de un ester/eter de polihematoporfirina.
DK0565519T3 (da) Illudinanaloge som antitumormidler
IT1264965B1 (it) Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce
ES2183890T3 (es) Uso del factor de crecimiento de hepatocitos para in estimular la proliferacion y diferenciacion de celulas hematopoyeticas.
EP0248217A3 (en) Treatment of tumors with autologous lak cells, interleukin-2 and an ornithine decarboxylase inhibitor
DE60308917D1 (de) Verwendung einer Zusammensetzung enthaltend 5-Androsten-3beta,17alpha-diol
ES2080114T3 (es) Procedimiento para preparar un factor inhibidor de la metastasis.
MX9701478A (es) Uso de il-4 para aumentar la potencia de agentes quimioterapeuticos.
ES2129047T3 (es) Metodo para mejorar la memoria y la calidad de vida.
DE68927762D1 (de) Elektronenquellenstruktur und ihre Anwendung bei Röhren zur Erzeugung elektromagnetischer Wellen
AU119855S (en) X-ray beam gradient
IT1274015B (it) Uso del ceruletide (takus) nel trattamento della psoriasi
AU112502S (en) an ornament

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees